ReviewJournal of gastroenterology and hepatology2026
The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.
Review in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in Malaysia. Early detection increases the likelihood of curative treatment and improves survival. This consensus document aims to provide evidence-based, locally relevant recommendations for the prevention and early detection of HCC.
methodsNineteen experts from gastroenterology and hepatology, radiology, endocrinology, and family medicine were convened by the Malaysian Society of Gastroenterology and Hepatology. A modified Delphi method was used to prepare the consensus statements.
resultsTwenty-two out of 26 statements achieved consensus and are included in this document. These statements addressed HCC prevention, risk stratification, surveillance strategies, barriers to effective surveillance, and recommendations on linkage to specialized hepatology care. Preventive measures include universal Hepatitis B vaccination for newborns, treatment of Hepatitis B and C, and lifestyle modification. Six-monthly surveillance with ultrasound and serum alpha-fetoprotein (AFP) is the current standard of care; however, adjunctive novel biomarkers and imaging can improve early HCC detection. Early identification of at-risk patients using noninvasive fibrosis assessment in the primary healthcare and endocrinology setting are equally important.
conclusionActive surveillance of at-risk patients is crucial in improving early HCC detection and patient survival. The efficacy of HCC surveillance requires greater awareness, better identification of at-risk patients and clear referral pathways, supported by multidisciplinary collaboration. This consensus document provides a practical, evidence-based approach to optimizing HCC prevention and early detection, with the goal of improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.